Life Science Reit Plc (LABS) AI Stock Analysis

• Market Cap: £130.20M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 4.55%
• EPS Growth: 23.43%
• Country: UK
• Employees: N/A
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Industrial
• EPS (TTM): 0.01
• Shares Outstanding: 350,000,000
• 10 Day Avg. Volume: 565,873
• 30 Day Avg. Volume: 1,260,832
• PEG Ratio: 0.27
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 6.55
• P/FCF Ratio: -20.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: 38.00p ▼(-2.81% Downside)

The overall stock score is primarily driven by significant financial instability and negative corporate events. The managed wind-down proposal and asset liquidation plan are major concerns, overshadowing any short-term technical strengths. The lack of profitability and negative valuation metrics further contribute to a low score.

Positive Factors

Strong Balance Sheet

A debt-free balance sheet provides financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of interest payments.

High Occupancy Rates

High occupancy rates driven by strategic partnerships enhance revenue stability and reduce vacancy risks, supporting long-term cash flow and profitability.

Industry Demand

Growing demand in the life sciences sector supports long-term leasing opportunities, ensuring sustained revenue growth and market relevance.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in maintaining market share and customer base, potentially impacting long-term financial health and growth prospects.

Negative Profitability

Negative profitability reflects operational inefficiencies and challenges in cost management, which can hinder the company's ability to generate sustainable profits.

Negative Free Cash Flow

Negative free cash flow suggests difficulties in managing capital expenditures and funding operations, potentially limiting growth and investment capabilities.

Life Science Reit Plc Business Overview & Revenue Model

Company Description

Life Science Reit Plc is an investment company, which intends to carry on business as a REIT. Its objective is to provide Shareholders with an attractive level of total return. The company was founded on July 27, 2021 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Life Science Reit Plc generates revenue primarily through leasing its properties to tenants in the life sciences sector. The company enters into long-term lease agreements with pharmaceutical companies, biotech firms, and research institutions, ensuring a steady stream of rental income. LABS also benefits from property appreciation over time, which enhances its asset value and overall portfolio. Additionally, the company may engage in partnerships with academic institutions or research organizations to further develop its real estate offerings, potentially leading to new revenue opportunities. The focus on a niche market allows LABS to capitalize on the increasing demand for specialized life sciences facilities, contributing to its financial growth.

Life Science Reit Plc Financial Statement Overview

Summary

Life Science Reit Plc shows financial instability with declining revenue and profitability challenges. Despite a strong balance sheet with no debt, the consistent negative free cash flow and negative profitability are concerns. The company needs to improve revenue generation and manage operational costs for sustainable growth.

Income Statement

The company's income statement reveals a volatile revenue trajectory and negative profitability. The negative total revenue in the latest year is a concerning trend, with a significant decline from positive revenue in 2023. Gross profit and net income margins are negative, indicating challenges in achieving profitability. The EBIT margin is also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively stable equity position with a high equity ratio, suggesting low leverage and a lower risk profile. The company has no total debt in the most recent year, which is a positive sign. However, the large fluctuations in stockholders' equity and total assets over the years indicate potential instability in asset management.

Cash Flow

Cash flow analysis highlights a mixed picture with positive operating cash flow in the latest year, yet persistent negative free cash flow. The operating cash flow to net income ratio is robust, showing the company's ability to convert earnings into cash. However, the negative free cash flow growth rate signals potential issues in managing capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.04M	20.31M	19.94M	15.71M	532.00K
Gross Profit	5.62M	11.45M	10.44M	7.15M	77.00K
EBITDA	9.16M	9.78M	8.72M	-65.04M	-302.00K
Net Income	-30.67M	-13.98M	-21.71M	-27.61M	7.74M
Balance Sheet
Total Assets	374.95M	401.19M	410.70M	447.82M	361.40M
Cash, Cash Equivalents and Short-Term Investments	4.72M	5.57M	14.34M	45.61M	165.96M
Total Debt	126.40M	122.24M	107.92M	109.83M	0.00
Total Liabilities	141.89M	138.42M	126.96M	128.37M	10.82M
Stockholders Equity	233.06M	262.77M	283.75M	319.45M	350.58M
Cash Flow
Free Cash Flow	-1.72M	-6.36M	-16.42M	-8.73M	3.54M
Operating Cash Flow	8.68M	12.92M	7.62M	-1.09M	3.54M
Investing Cash Flow	-11.17M	-16.35M	-11.64M	-186.38M	-181.52M
Financing Cash Flow	-3.30M	-5.34M	-27.24M	67.11M	343.94M

Life Science Reit Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 39.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:LABS, the sentiment is Negative. The current price of 39.1 is above the 20-day moving average (MA) of 38.31, above the 50-day MA of 38.30, and below the 200-day MA of 40.19, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 41.05 is Neutral, neither overbought nor oversold. The STOCH value of 54.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:LABS.

Life Science Reit Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SREI	66 Neutral	£276.35M	―	―	6.64%	―	―
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
ASLI	60 Neutral	£112.11M	16.19	2.31%	65.05%	0.54%	―
HLCL	55 Neutral	£226.07M	9.01	6.07%	2.71%	-14.09%	―
LABS	48 Neutral	£130.20M	-4.25	-12.26%	―	4.55%	23.43%

Life Science Reit Plc Corporate Events

Life Science REIT Hit by Portfolio Devaluation Amid Weaker Lab Demand

Life Science REIT reported that the value of its property portfolio fell 7.8% to £332.6 million as at 31 December 2025, while its unaudited EPRA net tangible assets declined 13% to £201.8 million, or 57.7 pence per share, reflecting weaker market valuations and higher leverage to fund ongoing development projects. The decline was driven mainly by outward yield shifts across the portfolio, exacerbated by softening laboratory demand caused by reduced venture capital and second-stage funding for life science companies, with the Cambourne Park Science and Technology Campus seeing the sharpest hit as persistent vacancies and capex needs led valuers to treat it as an office/business park rather than a prime life science asset; elsewhere, modest value declines were partly offset by improving demand and rising ERVs at Oxford Technology Park and a supportive lease regear at Herbrand Street in Bloomsbury, ahead of full-year results due in April 2026.

The most recent analyst rating on (GB:LABS) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on Life Science Reit Plc stock, see the GB:LABS Stock Forecast page.

Life Science REIT Appoints New Senior Independent Director

Life Science REIT plc has appointed Robert Naylor as the Senior Independent Non-Executive Director, replacing Richard Howell, who will remain as a Non-Executive Director and Chair of the Audit Committee. Naylor brings 29 years of experience in capital markets, particularly in the investment companies’ sector, and holds various directorships, which could enhance the company’s strategic direction and governance.

The most recent analyst rating on (GB:LABS) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on Life Science Reit Plc stock, see the GB:LABS Stock Forecast page.

Life Science REIT Approves New Investment Policy and Initiates Wind-Down

Life Science REIT plc announced the approval of a new investment objective and policy by its shareholders, which includes a managed wind-down of the company. The decision was made at a general meeting where the majority of shareholders voted in favor of the resolution. Additionally, the company served a two-year protective notice to terminate its investment advisory agreement with G10 Capital Limited and Ironstone Asset Management Limited, marking a significant shift in its operational strategy.

The most recent analyst rating on (GB:LABS) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on Life Science Reit Plc stock, see the GB:LABS Stock Forecast page.

Life Science REIT Proposes Managed Wind-Down and Asset Liquidation

Life Science REIT plc has announced the publication of a circular detailing a proposal for a Managed Wind-Down of the company, which includes a new investment objective and policy. This proposal, pending shareholder approval, aims to liquidate the company’s assets in an orderly manner over 12-18 months to repay borrowings and return capital to shareholders, ultimately leading to the cancellation of the company’s shares from the London Stock Exchange and the appointment of a liquidator.

The most recent analyst rating on (GB:LABS) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on Life Science Reit Plc stock, see the GB:LABS Stock Forecast page.